Dear readers,

Due to technical issues, the files for some articles may be temporarily unavailable for download or online viewing.
Until the restoration is complete, you can access the journal’s issues and articles via our partners’ platforms: https://elibrary.ru/ and https://journals.rcsi.science/
For Eco-Vector journal portal technical support, please contact support@eco-vector.com

Liposomes as target delivery of antitumor drugs


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Target delivery of antitumor drugs to cancer cells seems to be the very promising way of cancer therapy. The study on the application of immunoliposomes as nanocontainers for anticancer drugs started in the 90-ies. Immunoliposomal drug formulations of antitumor preparations have some advantages over traditional forms of drugs: lipid capsule reduces toxicity of drug due to the selective delivery to tumor and improves its bioavailability. However, despite these benefits, at present immunoliposomal drugs application is limited in the clinic. This review discusses current research status in field of development immunoliposomes and the possible targets for anticancer immuno-liposomes.

About the authors

A. O. Raikov

I. M. Sechenov First Moscow State Medical University

Author for correspondence.
Russian Federation

A. . Hashem

I. M. Sechenov First Moscow State Medical University

Russian Federation

M. A. Baryshnikova

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia

Email: ma_ba@mail.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)

✱ All the metadata of this work are dedicated to being read, copied, modified, distributed, and used for any purpose (even commercial), without asking permission.